{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:47:08Z","timestamp":1768679228973,"version":"3.49.0"},"reference-count":12,"publisher":"S. Karger AG","issue":"5","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Innate Immun"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>The course of COVID-19 is unpredictable, ranging from asymptomatic to respiratory failure and death. Prognostic biomarkers are urgently needed. We hypothesized that long pentraxin PTX3 could be a valuable plasma biomarker due to its essential role in inflammatory processes. In a prospective hospitalized COVID-19 derivation cohort (&lt;i&gt;n&lt;\/i&gt; = 126) during the spring of 2020, we measured PTX3 within 4 days of admission. The predictive value of mechanical ventilation (MV) and 30-day mortality compared with clinical parameters and other markers of inflammation were assessed by logistic regression analysis and expressed as odds ratio (OR) with 95% confidence interval (CI). Analyses were repeated in a prospective validation cohort (&lt;i&gt;n&lt;\/i&gt; = 112) of hospitalized patients with COVID-19 treated with remdesivir and dexamethasone. Thirty-day mortality in the derivation cohort was 26.2%. In patients who died, the median PTX3 concentration upon admission was 19.5 ng\/mL (IQR: 12.5\u201333.3) versus 6.6 ng\/mL (IQR 2.9\u201312.3) (&lt;i&gt;p&lt;\/i&gt; &amp;#x3c; 0.0001) for survivors. After adjustment for covariates, the odds of 30-day mortality increased two-fold for each doubling of PTX3 (OR 2.03 [95% CI: 1.23\u20133.34], &lt;i&gt;p&lt;\/i&gt; = 0.006), which was also observed in the validation cohort (OR 1.70 [95% CI: 1.09\u20132.67], &lt;i&gt;p&lt;\/i&gt; = 0.02). Similarly, PTX3 levels were associated with MV. After adjustment for covariates, OR of MV was 2.34 (95% CI: 1.33\u20134.12, &lt;i&gt;p&lt;\/i&gt; = 0.003) in the derivation cohort and 1.64 (95% CI: 1.03\u20132.62, &lt;i&gt;p&lt;\/i&gt; = 0.04) in the validation cohort. PTX3 appears to be a useful clinical biomarker to predict 30-day respiratory failure and mortality risk in COVID-19 patients treated with and without remdesivir and dexamethasone. <\/jats:p>","DOI":"10.1159\/000521612","type":"journal-article","created":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T09:47:17Z","timestamp":1643104037000},"page":"493-501","source":"Crossref","is-referenced-by-count":26,"title":["Prediction of Respiratory Failure and Mortality in COVID-19 Patients Using Long Pentraxin PTX3"],"prefix":"10.1159","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7709-4522","authenticated-orcid":false,"given":"Cecilie Bo","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e5kon","family":"Sandholdt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Elizabeth Engel","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0368-4976","authenticated-orcid":false,"given":"Laura","family":"P\u00e9rez-Al\u00f3s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0057-208X","authenticated-orcid":false,"given":"Lise","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0653-1289","authenticated-orcid":false,"given":"Simone","family":"Bastrup Israelsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-8586","authenticated-orcid":false,"given":"Peter","family":"Garred","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0698-9385","authenticated-orcid":false,"given":"Thomas","family":"Benfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2022,1,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2648"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-020-00217-0"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00016.2017"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI18921"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-030409-101305"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00754"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115756"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2016.04.007"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073119"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1038\/srep43045"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1515\/CCLM.2009.110"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13071"}],"container-title":["Journal of Innate Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/521612","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/521612","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:42:05Z","timestamp":1745422925000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000521612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":12,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,9,2]]}},"URL":"https:\/\/doi.org\/10.1159\/000521612","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.18857375","asserted-by":"subject"}]},"ISSN":["1662-811X","1662-8128"],"issn-type":[{"value":"1662-811X","type":"print"},{"value":"1662-8128","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]}}}